<DOC>
	<DOCNO>NCT00004872</DOCNO>
	<brief_summary>RATIONALE : Endostatin may stop growth solid tumor stop blood flow tumor . PURPOSE : Phase I trial study effectiveness endostatin treat patient advanced refractory solid tumor .</brief_summary>
	<brief_title>Endostatin Treating Patients With Advanced Refractory Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum tolerate dose ( MTD ) Phase II dose endostatin patient advance refractory solid tumor . II . Determine qualitative quantitative nature toxicity encounter endostatin patient population . III . Evaluate basic pharmacokinetics metabolism endostatin measurement plasma level EIA mass spectrometry patient population . IV . Investigate relationship pharmacokinetic parameter toxicity patient population . V. Evaluate biologic evidence angiogenesis inhibition patient receive endostatin . OUTLINE : This dose escalation study . Patients receive endostatin IV 1 hour daily 28 day , follow 1 week rest . Patients receive subsequent course daily therapy absence disease progression unacceptable toxicity . Cohorts 3 patient receive escalate dos endostatin maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 6 patient experience dose limit toxicity . PROJECTED ACCRUAL : Approximately 30-40 patient accrue study .</detailed_description>
	<mesh_term>Endostatins</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm advanced refractory solid tumor curative therapy exist Bidimensionally measurable evaluable disease accessible biopsy No brain metastasis primary brain tumor PATIENT CHARACTERISTICS : Age : Over 18 Performance status : ECOG 01 Life expectancy : Not specify Hematopoietic : WBC least 4,000/mm3 OR Absolute neutrophil count least 2,000/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin normal AST/SGOT great 2 time upper limit normal ( ULN ) Renal : Creatinine great 1.5 mg/dL OR Creatinine clearance great 60 mL/min Other : No serious active infection Not pregnant nursing Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : At least 4 week since prior chemotherapy Endocrine therapy : Not specify Radiotherapy : At least 4 week since prior radiotherapy recover Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
</DOC>